Back to Search
Start Over
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).
- Source :
-
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2009 Jul; Vol. 20 (7), pp. 1210-5. Date of Electronic Publication: 2009 Mar 02. - Publication Year :
- 2009
-
Abstract
- Background: This randomized, multicenter, phase III trial compared doxorubicin plus cyclophosphamide (AC), single-agent docetaxel (D), and an alternating regimen of AC and docetaxel (AC-D) as first-line chemotherapy in metastatic breast cancer (MBC).<br />Patients and Methods: Patients with MBC resistant to endocrine therapy were entered in a randomized study to receive either six cycles of AC (doxorubicin 40 mg/m2 plus cyclophosphamide 500 mg/m2), D (60 mg/m2), or alternating treatment with AC-D (i.e. three cycles of AC and three cycles of D). Treatment was administered every 3 weeks.<br />Results: A total of 441 patients were entered in a randomized study. Response rates were 30% for AC, 41% for D, and 35% for AC-D. The median times to treatment failure (TTFs) were 6.4, 6.4, and 6.7 months (one-sided log-rank test, P = 0.13 for AC versus D, P = 0.14 for AC versus AC-D) and median overall survival (OS) was 22.6, 25.7, and 25.0 months (P = 0.09 for AC versus D, P = 0.13 for AC versus AC-D) in the AC, D, and AC-D, respectively.<br />Conclusion: There was no difference in the TTF among the three arms. However, there was a trend toward a better response and better OS in the D than in the AC.
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols administration & dosage
Breast Neoplasms pathology
Cyclophosphamide administration & dosage
Docetaxel
Doxorubicin administration & dosage
Drug Administration Schedule
Female
Humans
Neoplasm Metastasis
Taxoids administration & dosage
Time Factors
Treatment Failure
Treatment Outcome
Antineoplastic Agents administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Breast Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1569-8041
- Volume :
- 20
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Annals of oncology : official journal of the European Society for Medical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 19254942
- Full Text :
- https://doi.org/10.1093/annonc/mdn781